about
Prognostic Significance of Right Heart Thrombi in Patients With Acute Symptomatic Pulmonary Embolism: Systematic Review and Meta-analysis.Centrilobular nodules in high resolution computed tomography of the lung in IPAH patients - preliminary data concerning clinico-radiological correlates.SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHINManagement of venous thrombo-embolism: an update.The pathophysiology of chronic thromboembolic pulmonary hypertension.Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function.Low DLCO in idiopathic pulmonary arterial hypertension - clinical correlates and prognostic significance.Changing the strategy of balloon pulmonary angioplasty resulted in a reduced complication rate in patients with chronic thromboembolic pulmonary hypertension. A single-centre European experience.Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry.Outcome of patients with right heart thrombi: the Right Heart Thrombi European Registry.Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.Severity of arterial and chronic thromboembolic pulmonary hypertension is associated with impairment of heart rate turbulence.Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil.Improvement in Quality of Life and Hemodynamics in Chronic Thromboembolic Pulmonary Hypertension Treated With Balloon Pulmonary Angioplasty.EXPRESS: Acute and chronic dissection of pulmonary artery: new challenges in pulmonary arterial hypertension?The importance of psychosocial factors in management of pulmonary arterial hypertension patients.Macitentan for treatment of CTEPH: why MERIT merits attention.2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS).Contemporary methods for the treatment of pulmonary embolism - is it prime-time for percutaneous interventions?The "bouncing" catheter.Vena cava superior stenting for rescue treatment of critical stenosis related to progressing cancer disease.[Pulmonary hypertension in contemporary imaging. Expert consensus statement of the Polish Clinical Forum for Cardiovascular Imaging].Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis.[A statement the Polish Cardiac Society Working Group on Pulmonary Circulation on screening for CTEPH patients after acute pulmonary embolism].Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.2013 ESC guidelines on the management of stable coronary artery diseaseSequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamicsBalloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomyResponse to letter from dr Altmayer regarding publication "Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamicsDiagnosis of pulmonary hypertensionAugmented reality and three-dimensional printing in percutaneous interventions on pulmonary arteriesCorrigendum to:2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism:Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare DiseasesPregnancy as a predictor of deviations from the recommended diagnostic pathway in women with suspected pulmonary embolism: ZATPOL registry data.Outcome of Medically Versus Surgically Treated Patients With Chronic Thromboembolic Pulmonary HypertensionHypertension: Definition of pulmonary hypertension challenged?Sarcoidosis-associated pulmonary hypertension treated with sildenafil - a case reportChanges in Estimated Glomerular Filtration after Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
P50
Q30244485-8CAB39B7-F022-4B33-BF6B-197C7783BF31Q31133300-B8012814-87C5-43B2-A9A9-166577C88474Q33589653-317663B9-D46A-404D-90E3-3AA7402F22F0Q36332690-5AB16D2F-9C12-4D27-ACFA-DA59224BF7C6Q38245422-1FBCC8D2-98FD-4BFA-8231-5C5F1528A37AQ39207429-07403493-48D4-4AAB-B153-DCC4B4D86562Q39229601-9DED5657-F9A7-4AF5-A17E-5AEF75DB421DQ39727305-ABCF4285-DF20-48F4-BE97-342BEA351D2EQ40182075-6109D582-E4A5-4531-B2DA-1241F6BC4AB7Q40941203-34B33DAA-0CC3-4FEC-A1A8-AD59B78BCA96Q40958867-3CB9337C-F59E-4184-940A-39D278C351ECQ41143611-A8BDBDF8-2FBB-4063-AD94-E88AC1A6145CQ45176674-C0429042-58AA-4CD5-BB6B-F77842D58A4DQ46126985-CDA200F2-52DC-4A5A-BBC5-1E275034D6F3Q47110514-19BF510C-065F-464C-BA8A-2934C5BE3393Q47580200-B0EE765D-6B47-4012-B902-67A1F1D391B4Q49685666-EC06051C-B9AE-4B3E-9D5C-6C874B9B4D4CQ49923899-4F52A3C3-1094-4A1A-B823-4D4EBF873E35Q50053508-F343EA9F-F00E-4124-87D3-56588283EAA2Q50278701-FCDD867F-A3BF-4AD3-A03D-7134B0933A19Q50527712-BA3D66FD-9B8F-4B61-85EE-D4959DA96A21Q51141238-9A19A7E3-45C6-4582-8B43-402784D6976DQ51270333-F1B25D9C-EFCC-4E75-8107-6F0D537E38B3Q53699383-A036FE10-74CC-4698-878F-CD9CF3BBA086Q54267483-88D73AB6-FC12-40CA-8DCF-3C24BABFF2FCQ54299864-A03B22AE-020A-4662-A940-FBCE8FDE5D01Q55020470-D3283FD4-E792-42A5-81ED-543325CE5DF8Q57243329-4F22DDBA-9ADA-4B96-8D93-22EEF560EFBAQ57463963-B2420EF5-648B-4C20-8B80-6F69F4B67B03Q58557488-8D4A3107-F876-4F41-893B-8D7D80596DF1Q58592267-AD6E3D63-F262-419D-BCC9-2895E073DAA0Q61810192-67732DD3-EF46-4D77-A4AF-C9D6718CBE3BQ61810498-B77DD497-A95D-4C14-8026-4DDC99A1271DQ61894848-F13E8A67-210E-403A-BAFA-CE1656E6D79FQ64039266-E73EF662-3BF7-41A7-9242-DC212BD2FB31Q64902165-FFCD9722-5E5C-4804-BB23-0E57A63A121DQ87980586-934AB0B8-3CEB-41F3-A22F-956A7AE52F7EQ89051969-6C41313D-A4C5-49E7-8ACC-2657F8CFF1DEQ89767360-57EB5F28-449E-4C1A-84E3-ED9FC5282ECBQ90132756-91E6D797-8021-488E-9D94-D2500BF20B56
P50
description
investigador
@es
researcher
@en
name
Adam Torbicki
@en
type
label
Adam Torbicki
@en
prefLabel
Adam Torbicki
@en
P31
P496
0000-0003-3475-8832